Development of support system for dosage adjustment to avoid drug-drug interactions caused by fluoropyrimidine anti-cancer drugs

2014 Fiscal Year Final Research Report

• Project/Area Number: 24390038
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: Medical pharmacy
• Research Institution: The University of Tokyo
• Principal Investigator: SAWADA Yasufumi 東京大学, 大学院薬学系研究科, 教授 (80114502)
• Co-Investigator(Kenkyū-buntansha): HORI Satoko 東京大学, 大学院情報学環, 准教授 (70313145) ; SATOH Hiroki 東京大学, 大学院薬学系研究科, 助教 (80451855)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 薬物間相互作用 / フッ化ピリミジン系抗癌薬 / 薬物代謝酵素 / フェニトイン / ワルファリン

Outline of Final Research Achievements

Fluoropyrimidine anti-cancer drugs cause the drug-drug interactions with anti-epileptic drugs (phenytoin) and anticoagulants (warfarin). In this study, we conducted experiment using HepaRG cells, and then elucidated the mechanism of this interaction. Also, we collected cases which were co-administrated fluoropyrimidine anti-cancer drugs and phenytoin or warfarin, and constructed pharmacokinetic-pharmacodynamic model that can represent the interaction. When used in combination with fluoropyrimidine anti-cancer drugs, it is possible to predict a phenytoin dosage as not to vary the phenytoin concentration using the constructed models.

Free Research Field

臨床薬物動態学